Deutsche Bank’s Actuate Therapeutics ACTU Stock Holding History

Deutsche Bank’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-12,235	Closed	-$18.7K	–	3779
2026 Q2	$18.7K	Sell	12,235 -24,163	-66%	-$56K	﹤0.01%	3611
2026 Q1	$100K	Buy	36,398 +27,089	+291%	+$112K	﹤0.01%	3282
2025 Q4	$57K	Buy	9,309 +8,051	+640%	+$55.3K	﹤0.01%	3430
2025 Q3	$8.42K	Sell	1,258 -9,181	-88%	-$66.6K	﹤0.01%	3525
2025 Q2	$63.8K	Buy	+10,439	New	+$91.2K	﹤0.01%	3381

Other funds holding ACTU

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Deutsche Bank's ACTU Position: Q3 2026 in Review

Deutsche Bank sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 12,235 shares — an estimated $18.7K sold.

Deutsche Bank first reported a position in ACTU in Q2 2025 and held it in 5 quarters. The position peaked at $100K in Q1 2026. 12 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

Deutsche Bank reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
Deutsche Bank sold 12,235 Actuate Therapeutics shares in Q3 2026, an estimated $18.7K.
Deutsche Bank first reported a position in Actuate Therapeutics in Q2 2025 and held it in 5 quarters.
Deutsche Bank's Actuate Therapeutics position peaked at $100K in Q1 2026.
12 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.